Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Chongqing University Cancer Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07543848CT.gov A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07397442CT.gov Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07474103CT.gov SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC | — | Recruiting | — | — | — |
NCT07407465CT.gov Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT06780787CT.gov FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | — | Recruiting | — | — | — |
NCT06919510CT.gov A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06266832CT.gov The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | — | Recruiting | — | — | — |
NCT06108596CT.gov Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail | — | Completed | — | — | — |
NCT04418895CT.gov Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | — | Withdrawn | — | — | — |
NCT04406857CT.gov Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer | — | Terminated | — | — | — |
Show 9 more trialsShow fewer
NCT04621370CT.gov A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer | — | Unknown | — | — | — |
NCT04165772CT.gov Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | — | Recruiting | — | — | — |
NCT03300544CT.gov Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | — | Terminated | — | — | — |
NCT02945566CT.gov Can We Save the Rectum by Watchful Waiting or TransAnal Surgery Following (chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | — | Active Not Recruiting | — | — | — |
NCT02921256CT.gov Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT02688712CT.gov ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT01634685CT.gov A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma | — | Completed | — | — | — |
NCT01134601CT.gov A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum | — | Terminated | — | — | — |
NCT00026234CT.gov Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectum Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Chongqing University Cancer Hospital | P3 | B · 63 |
| Fluorouracilum | Merck Sharp & Dohme LLC | P3 | BBB |
| Irinotecan | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BBB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
| Trifluridine | Sir Run Run Shaw Hospital | P2 | BB |
| Regorafenib | City of Hope Medical Center | P2 | BB |
| Tipiracil | Sir Run Run Shaw Hospital | P2 | BB |
+42 more in the Rectum Adenocarcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Rectum Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-rectum-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →